144 - Definium Therapeutics, Inc. (0001813814) (Subject)

10-K - Definium Therapeutics, Inc. (0001813814) (Filer)

8-K - Definium Therapeutics, Inc. (0001813814) (Filer)

SCHEDULE 13G - Definium Therapeutics, Inc. (0001813814) (Subject)

SCHEDULE 13G - Definium Therapeutics, Inc. (0001813814) (Subject)

8-K - Definium Therapeutics, Inc. (0001813814) (Filer)

4 - Definium Therapeutics, Inc. (0001813814) (Issuer)

4 - Definium Therapeutics, Inc. (0001813814) (Issuer)

4 - Definium Therapeutics, Inc. (0001813814) (Issuer)

4 - Definium Therapeutics, Inc. (0001813814) (Issuer)

4 - Definium Therapeutics, Inc. (0001813814) (Issuer)

4 - Definium Therapeutics, Inc. (0001813814) (Issuer)

4 - Definium Therapeutics, Inc. (0001813814) (Issuer)

4 - Definium Therapeutics, Inc. (0001813814) (Issuer)

4 - Definium Therapeutics, Inc. (0001813814) (Issuer)

3 - Definium Therapeutics, Inc. (0001813814) (Issuer)

Wolfe Research initiated coverage of Definium Therapeutics with a rating of Outperform and set a new price target of $25.00

Jefferies initiated coverage of Definium Therapeutics with a rating of Buy and set a new price target of $30.00

The annual prevalence of newly diagnosed generalized anxiety disorder (GAD) increased from 5.4% in 2020 to 6.6% in 2023 The 3-year total prevalence of GAD reached 10.3%, representing more than 1 in 10 U.S. adults Definium Therapeutics, Inc. ("Definium" or the "Company"), announced results from a retrospective, longitudinal study published in the Journal of Mood and Anxiety Disorders examining the real-world prevalence, incidence, and burden of GAD in the United States healthcare system from 2020 to 2023. These findings show a steadily increasing diagnosed prevalence of GAD and highlight a substantial and growing burden affecting more than 1 in 10 adults in the U.S. Together, these resul

Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 55,580 common shares of the Company (the "Options") with effective grant dates of March 16, 2026 and March 30, 2026. The Options have an exercise price equal to the closing price of Definium's common shares on the date of the respective grant, and will vest over a four-year period with 25% vesting on the first anniversar

Definium Therapeutics, Inc. (NASDAQ:DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced additional details for its Investor & Analyst Day in New York on April 22, 2026. Presentations and live question and answer sessions will be led by members of Definium's executive leadership team and external key opinion leaders who will provide clinical and real-world context on the evolving treatment landscape in generalized anxiety disorder (GAD) and major depressive disorder (MDD). Key areas of discussion will include DT120 ODT (lysergide tartrate), Defin

Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of (i) options to purchase an aggregate of 134,540 common shares of the Company (the "Options") and (ii) 34,500 performance share units (the "PSUs") (assuming achievement at target levels of performance) that, if earned, will be settled in Definium common shares upon vesting, with effective grant dates of February 24, 2026, February 27, 2026 and March 9, 2026.

Issued on behalf of Cybin D/B/A Helus PharmaUSANewsGroup.com News CommentaryVANCOUVER, BC, March 9, 2026 /CNW/ -- The central nervous system therapeutics sector is approaching a commercial inflection point as multiple candidates advance through late-stage trials and regulatory milestones accumulate1. The Drug Enforcement Administration raised its 2026 production quotas for controlled research compounds by 67%, reflecting expanding clinical trial activity across the therapeutics landscape2. Five companies are working to translate that momentum into approved treatments: Helus Pharma (NASDAQ:HELP), Compass Pathways (NASDAQ:CMPS), AtaiBeckley (NASDAQ:ATAI), Definium Therapeutics (NASDAQ:DFTX), a

Issued on behalf of Helus PharmaVANCOUVER, BC, Feb. 27, 2026 /CNW/ -- Equity-Insider.com News Commentary -- Psychedelic compounds are edging closer to regulatory approval as pivotal trials in treatment-resistant depression and anxiety advance through late-stage development[1]. The sector is shedding its countercultural reputation as biotech firms reposition serotonergic and psychedelic-derived therapies as mainstream pharmaceutical candidates[2]. Five companies are building the clinical programs to get there: Helus Pharma (NASDAQ:HELP), AtaiBeckley (NASDAQ:ATAI), Definium Therapeutics (NASDAQ:DFTX), GH Research (NASDAQ:GHRS), and LB Pharmaceuticals (NASDAQ:LBRX).

Emerge (Phase 3 MDD) enrollment complete; topline data anticipated in late 2Q 2026 Voyage (Phase 3 GAD) approximately 80% enrolled; no change in sample size required; topline readout anticipated in early 3Q 2026 Panorama (Phase 3 GAD) enrollment on track; topline readout expected in 2H 2026 $411.6 million in cash, cash equivalents and investments as of December 31, 2025 expected to fund operations into 2028 Conference call scheduled today at 4:30 p.m. EST Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorder

Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ:DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company's management team will participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference Presentation Date and Time: Monday, March 2, 2026 at 9:10 AM ET Location: Boston, MA Webcast Link: TD Cowen 46th Annual Health Care Conference Jefferies Biotech on the Beach Summit Date: Tuesday, March 10, 2026 Location: Miami Beach, FL Leerink Partner

Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ:DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a live webcast at 4:30 p.m. EST on Thursday, February 26, 2026 to report financial results for the full year ended December 31, 2025, and discuss recent business updates. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the Definium

Seasoned biopharmaceutical leader brings deep commercial, operational, and launch expertise to support Definium's next phase of growth Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) today announced the appointment of Roger Adsett to its Board of Directors effective immediately. "We are thrilled to welcome Roger to our Board of Directors," said Rob Barrow, Chief Executive Officer of Definium Therapeutics. "Roger is a respected and proven leader with deep experience building high-performing commercial organizations and guiding transformational therapies from launch to meaningful market impact. At Insmed, he's led the development of world-class commercial and operation